Physician profile
Jose Rafael Carlo Izquierdo
NPI 1710023668
$49,153.02
in general payments reported to CMS, 2019-2025
23 companies · $37K in 2025
The $37K reported for 2025 was more than what 99% of Pain Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $405).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,332 · 2020: $303 · 2021: $318 · 2022: $4,406 · 2023: $3,900 · 2024: $700 · 2025: $37K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Consulting Fee: $6,600 · Travel and Lodging: $4,977 · Food and Beverage: $2,777 · Education: $73.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,367.50 |
| Consulting Fee | $6,600.00 |
| Travel and Lodging | $4,976.56 |
| Food and Beverage | $2,776.60 |
| Education | $73.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $20,535.06 | 2024-2025 | Uplizna |
| Argenx US, INC. | $16,220.81 | 2025 | Vyvgart, Vyvgart Hytrulo |
| Genzyme Corporation | $9,696.02 | 2019-2023 | |
| Alexion Pharmaceuticals, INC. | $696.69 | 2019-2025 | Ultomiris |
| Biogen, INC. | $680.56 | 2020-2025 | Vumerity, Tysabri, Plegridy |
| Novartis Pharmaceuticals Corporation | $237.89 | 2021-2025 | |
| Tanabe Pharma America, INC. | $216.39 | 2019 | |
| Genentech USA, INC. | $150.48 | 2019-2025 | Ocrevus Zunovo, Ocrevus |
| Akcea Therapeutics, INC. | $128.59 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $96.83 | 2020-2021 | |
| Ucb, INC. | $81.92 | 2019-2024 | Rystiggo |
| Abbvie INC. | $74.17 | 2024-2025 | |
| Eli Lilly Export S.A. Puerto Rico Branch | $60.85 | 2019-2021 | |
| Emd Serono, INC. | $46.61 | 2023 | Mavenclad |
| Ptc Therapeutics, INC. | $37.61 | 2024 | Emflaza |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $36.59 | 2023-2025 | Xarelto |
| Eisai INC. | $26.60 | 2025 | |
| Alnylam Pharmaceuticals INC. | $25.54 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $24.09 | 2021 | |
| Banner Life Sciences, LLC | $21.14 | 2022 | |
| Acorda Therapeutics, INC | $20.41 | 2019 | |
| Csl Behring | $19.85 | 2019 | |
| Pfizer Pharmaceuticals LLC | $18.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Carlo Izquierdo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.